Xenetic Biosciences, Inc. (XBIO) |
|
0.424 0.004 (0.98%)
|
03-24 11:01 |
|
Open: |
0.42 |
Pre. Close: |
0.4199 |
|
High:
|
0.424 |
Low:
|
0.42 |
|
Volume:
|
1,115 |
Market Cap:
|
6(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 10:48:58 AM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 0.58 One year: 0.7 |
| Support: |
Support1: 0.33 Support2: 0.27 |
| Resistance: |
Resistance1: 0.49 Resistance2: 0.6 |
| Pivot: |
0.41  |
| Moving Average: |
MA(5): 0.42 MA(20): 0.43
MA(100): 0.45 MA(250): 0.63 |
| MACD: |
MACD(12,26): -0.1  Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 52.9 %D(3): 46 |
| RSI: |
RSI(14): 43.1 |
| 52-week: |
High: 1.25 Low: 0.23 |
| Average Vol(K): |
3-Month: 62 (K) 10-Days: 36 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ XBIO ] has closed below upper band by 39.7%. Bollinger Bands are 36.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.42 - 0.42 |
0.42 - 0.42 |
|
Low:
|
0.4 - 0.41 |
0.41 - 0.41 |
|
Close:
|
0.42 - 0.42 |
0.42 - 0.42 |
|
Company Description |
|
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts. |
Headline News |
Mon, 20 Mar 2023
Febrile Neutropenia Market to Witness Growth by 2032, Estimates ... - Digital Journal
Thu, 16 Mar 2023
JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences - Yahoo Finance
Thu, 09 Feb 2023
Soligenix to implement 1-for-15 reverse stock split (NASDAQ:SNGX) - Seeking Alpha
Tue, 17 Jan 2023
Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy - Yahoo Finance
Thu, 01 Dec 2022
This Is Why Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Looks Appropriate - Yahoo Finance
Mon, 28 Nov 2022
KTRA stock jumps on FDA Fast Track status for breast cancer ... - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
15 (M) |
| Shares Float |
13 (M) |
|
% Held by Insiders
|
13.8 (%) |
|
% Held by Institutions
|
6.5 (%) |
|
Shares Short
|
43 (K) |
|
Shares Short P.Month
|
28 (K) |
Stock Financials |
|
EPS
|
-1.71 |
|
EPS Est Next Qtl
|
-0.26 |
|
EPS Est This Year
|
-0.89 |
|
EPS Est Next Year
|
-1.15 |
|
Book Value (p.s.)
|
1.39 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-452.8 |
|
Return on Assets (ttm)
|
-23.9 |
|
Return on Equity (ttm)
|
-39.9 |
|
Qtrly Rev. Growth
|
18.6 |
|
Gross Profit (p.s.)
|
0.07 |
|
Sales Per Share
|
0.1 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-5 (M) |
|
Levered Free Cash Flow
|
-4 (M) |
Stock Valuations |
|
PE Ratio
|
-0.25 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.3 |
|
Price to Sales
|
4.15 |
|
Price to Cash Flow
|
-1.21 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-06-24 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
